Xeris Biopharma combines 38% revenue growth and a Rule-of-40 pass with an overbought, late-cycle momentum setup (RSI 89) and value-trap warning signs — 19.9x leverage and modest insider selling — that the engine flags as risk.
Thesis pillars
- Strong Growth Positive Momentum→Stable
- Elevated Leverage Value Trap Risk→Stable
- Overbought Late Cycle Distribution Risk↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 2, 2026
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $9.36. At $10.71 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $9.36 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa.
Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic endocrine and neurological diseases in the United States: Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe hypoglycemia, and Keveyis for... Read more
Wait for pullback to $9.36. At $10.71 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $9.36 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 2 days. Wait until post-earnings. Score 5.9/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 2d<=7d. Suitability: aggressive.
About Xeris Biopharma Holdings, Inc.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma markets three FDA-approved products in the United States: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis, alongside a Phase 3-ready pipeline candidate, XP-8121, for hypothyroidism. The company turned profitable in 2025 with net income of $0.6 million, following net losses of $54.8 million in 2024 and $62.3 million in 2023, while carrying $200.0 million in term loans and $33.6 million in convertible notes.
Xeris generates revenue through U.S. prescription sales of Recorlev, Gvoke, and Keveyis, distributed via specialty pharmacies and wholesale customers under commercial agreements with a limited number of logistics vendors. The company outsources all manufacturing to third-party CMOs rather than operating its own facilities: Regis Technologies is the company's sole source for levoketoconazole, the active ingredient in Recorlev, and Lonza Tampa is its sole source for Recorlev's finished drug product, while Bachem Americas serves as primary source for Gvoke's glucagon API and Pyramid Laboratories as primary source for Gvoke's finished drug product. Taro Pharmaceuticals manufactures Keveyis under a supply agreement that lets Xeris manufacture the product itself or through another third party if Taro doesn't renew. Xeris also pursues formulation partnerships that license its XeriSol and XeriJect non-aqueous injectable technologies to other pharmaceutical companies' proprietary drugs and biologics, a secondary, royalty-oriented revenue stream distinct from its own product sales.
Show full overview
Keveyis illustrates the patent-cliff risk facing Xeris's older assets: the product lost orphan drug exclusivity in August 2022, and the FDA approved generic dichlorphenamide versions in 2022 and again in November 2025, most recently to Rising Pharmaceuticals, while Xeris's own attempt to restore exclusive rights through two pending patent applications remains on appeal at the Federal Circuit. Recorlev, by contrast, retains patent protection through 2040 and orphan exclusivity through December 30, 2028, positioning it as the more durable of the company's three approved products even as Keveyis faces mounting generic competition.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Xeris Biopharma Holdings, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — Xeris Biopharma Holdings, Inc.
Latest news
- NEWS Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
- NEWS Xeris Announces Details for XP-8121 Program Overview Webinar - Business Wire — Business Wire neutral
- NEWS Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat — MarketBeat positive
- NEWS Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm — Sahm positive
Generated 2026-11-02T11:43:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierRegis Technologies10-K Item 1: 'Regis Technologies, Inc. ... its facility in Illinois is our sole source for API.'
- HIGHSupplierLonza Tampa10-K Item 1: 'Lonza Tampa, LLC ... its facility in Florida is our sole source for drug product.'
- MEDIUMSupplierBachem10-K Item 1: 'Bachem Americas, Inc., ... is our primary commercial source for glucagon API.'
- MEDIUMSupplierPyramid Laboratories10-K Item 1: 'Pyramid Laboratories, Inc. ... Its facility in California is our primary source for drug product.'
Material Events(8-K, last 90d)
- 2026-06-30Item 5.02LOWBoard expanded from 7 to 8 members and appointed Nerissa Kreher, M.D. as a Class III director effective July 1, 2026. Routine board expansion, no departure involved.SEC filing →
- 2026-04-21Item 5.02LOWDirector Jeffrey Sherman notified the company on April 20, 2026 he will retire from the Board and not stand for reelection at the 2026 Annual Meeting; board size to shrink from 8 to 7. Explicitly not due to any disagreement with the company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $9.36. At $10.71 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $9.36 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 2 days. Wait until post-earnings. Target $11.19 (+4.5%), stop $8.85 (−21.0%), A.R:R 0.3:1. Score 5.9/10, moderate confidence.
Take-profit target: $11.19 (+4.4% upside). Target $11.19 (+4.5%), stop $8.85 (−21.0%), A.R:R 0.3:1. Stop-loss: $8.85.
Concentration risk — Supplier: Regis Technologies; Concentration risk — Supplier: Lonza Tampa; Thin upside margin: 4.4%.
Xeris Biopharma Holdings, Inc. trades at a P/E of N/A (forward 54.5). TrendMatrix value score: 4.7/10. Verdict: Buy (Wait for Entry).
13 analysts cover XERS with a consensus score of 4.2/5. Average price target: $13.
What does Xeris Biopharma Holdings, Inc. do?Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic...
Xeris Biopharma is a commercial-stage biopharmaceutical company selling three FDA-approved therapies for chronic endocrine and neurological diseases in the United States: Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe hypoglycemia, and Keveyis for periodic paralysis. The company reported net income of $0.6 million in 2025, a turnaround from net losses of $54.8 million and $62.3 million in 2024 and 2023, and relies on third-party contract manufacturers, including sole-source suppliers for two of Recorlev's key inputs.